IP Library Granted Patent US 9,238,815
Granted Patent B2
US 9,238,815 · App. 13/514,783 · Granted Jan 19, 2016

Compositions and methods for inhibiting human host factors required for influenza virus replication

Inventors: Megan Shaw (New York, NY); Peter Palese (Leonia, NJ); Adolfo Garcia-Sastre (New York, NY); Silke Stertz (Zurich, CH); John Young (San Diego, CA); Renate König (San Diego, CA); Sumit Chanda (La Jolla, CA)
Assignees: Icahn School of Medicine at Mounta Sinai; Salk Institute for Biological Studies; Sanford-Burnham Medical Research Institute
C12N15/1131A61K31/18A61K31/365
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,238,815
App. No.
13/514,783
Granted
Jan 19, 2016
Kind
B2
Abstract

This application relates to the modulation of host cell factors required for influenza virus replication. The application relates to compounds, including nucleic acid compounds (such as, e.g., small interfering RNAs (siRNAs)) and small molecules, that target human host cell factors involved in influenza virus replication, and the use of such compounds for modulating influenza virus replication and as antiviral agents. The application also relates to methods of treating an influenza virus infection and methods of treating or preventing a symptom or disease associated with influenza virus infection, comprising administering to a subject a composition comprising a compound, such as a nucleic acid compound (e.g., an siRNA) or small molecule, that targets a human host cell factor involved in influenza virus replication.

Claims (5)

1. A method of inhibiting replication of an influenza virus in a human subject, or treating or managing an influenza virus infection, or a symptom or disease associated therewith, in a human subject, comprising administering to a human subject in need thereof an effective amount of compound KN-93.

2. The method of claim 1 , in which the method is inhibiting replication of an influenza virus in a human subject.

3. The method of claim 1 , in which the method is treating or managing an influenza virus infection, or a symptom or disease associated therewith, in a human subject.

4. The method of claim 1 , wherein the influenza virus is an influenza A virus.

5. The method of claim 4 , wherein the influenza A virus is an H1N1 virus.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2015
From: YOUNG, JOHN
To: SALK INSTITUTE FOR BIOLOGICAL STUDIES
Reel/Frame 037036/0797 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2015
From: CHANDA, SUMIT; KÖNIG, RENATE
To: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Reel/Frame 037036/0864 →
CHANGE OF NAME Recorded Mar 25, 2013
From: MOUNT SINAI SCHOOL OF MEDICINE
To: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Reel/Frame 030081/0058 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2013
From: SHAW, MEGAN; STERTZ, SILKE; GARCIA-SASTRE, ADOLFO; PALESE, PETER
To: MOUNT SINAI SCHOOL OF MEDICINE
Reel/Frame 030069/0309 →
Continuity (2)
Provisional Application 61285951 · Dec 11, 2009
Related Publication 20130090367A1 · Apr 11, 2013